InsidersTradesSigma
Total declarations
Companies
▲ Purchases (21 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
21
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
-19.7%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Sanofi. Director active across 4 companies, notably Icosavax, Inc.. Aggregated, 23 filings have been logged. Split: 21 buys · 0 sell. Total volume traded: €3.3bn. History available since 2 August 2021. The latest transaction was disclosed on 14 September 2021 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations23 total
51,467,612 shares@ US$38.0050.0% of flowCommon Stock, par value $0.001 per shareSEC:0000899243-21-035757:0
Ideal exit: 11 Jun 2022 (T+270)
51,467,612 shares@ US$38.0050.0% of flowCommon Stock, par value $0.001 per shareSEC:0000899243-21-035757
Ideal exit: 11 Jun 2022 (T+270)
3,088,502 shares0Common Stock (par value, $0.0001)SEC:0000899243-21-031120
3,088,502 shares0Common Stock (par value, $0.0001)SEC:0000899243-21-031120:0
205,030 sharesCommon StockSEC:0000899243-16-012604:0
Ideal exit: 28 Oct 2016 (T+270)
5,007 sharesCommon StockSEC:0001140361-16-047842:0
Ideal exit: 8 Oct 2016 (T+270)
2,407 sharesCommon StockSEC:0001140361-16-047842:1
Ideal exit: 8 Oct 2016 (T+270)
2,164 sharesCommon StockSEC:0001140361-16-047842:2
Ideal exit: 8 Oct 2016 (T+270)
3,220 sharesCommon StockSEC:0001140361-16-047842:3
Ideal exit: 8 Oct 2016 (T+270)
3,100 sharesCommon StockSEC:0001140361-16-047842:4
Ideal exit: 8 Oct 2016 (T+270)
2,500 sharesCommon StockSEC:0001140361-16-047842:5
Ideal exit: 8 Oct 2016 (T+270)
3,563 sharesCommon StockSEC:0001140361-16-047842:6
Ideal exit: 8 Oct 2016 (T+270)
4,941 sharesCommon StockSEC:0001140361-16-047842:7
Ideal exit: 8 Oct 2016 (T+270)
2,759 sharesCommon StockSEC:0001140361-16-047842:8
Ideal exit: 8 Oct 2016 (T+270)
4,148 sharesCommon StockSEC:0001140361-16-047842:9
Ideal exit: 8 Oct 2016 (T+270)
8,002 sharesCommon StockSEC:0001140361-16-047842:10
Ideal exit: 8 Oct 2016 (T+270)
3,608 sharesCommon StockSEC:0001140361-16-047842:11
Ideal exit: 8 Oct 2016 (T+270)
4,901 sharesCommon StockSEC:0001140361-16-047842:12
Ideal exit: 8 Oct 2016 (T+270)
5,082 sharesCommon StockSEC:0001140361-16-047842:13
Ideal exit: 8 Oct 2016 (T+270)
7,204 sharesCommon StockSEC:0001140361-16-047842:15
Ideal exit: 8 Oct 2016 (T+270)
3,600 sharesCommon StockSEC:0001140361-16-047842:16
Ideal exit: 8 Oct 2016 (T+270)
3,563 sharesCommon StockSEC:0001140361-16-047842:17
Ideal exit: 8 Oct 2016 (T+270)
14,169 sharesCommon StockSEC:0001140361-16-047842:14
Ideal exit: 8 Oct 2016 (T+270)
23 of 23 declarations
About Sanofi
Sanofi is a declarant who has made a total of 23 filings. In its most recent filings, it acquired shares of Translate Bio, Inc. for a total amount of 1,656,732,202.80 EUR on September 14, 2021. It also acquired shares of ALNYLAM PHARMACEUTICALS, INC. on February 3, 2016, as well as shares of REGENERON PHARMACEUTICALS INC. on January 14, 2016. Sanofi holds 10% of REGENERON PHARMACEUTICALS INC. and 10% of ALNYLAM PHARMACEUTICALS, INC. The transactions are primarily acquisitions, with total purchases amounting to 3,313,464,406 EUR and no sales.
